CD4 and myeloid sarcoma: CD4 counts: Using a median cut-off point of 394 cells/μL, MS prevalence in participants with high CD4 counts was significantly lower than in those with low CD4 counts by the IDF 2005 criteria: 10.4% (8.2–12.9) vs. 17.5% (14.4–20.8), p<0.001 (S6 Table).